Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

12 Customer Reviews

  • PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

    Assessment of effects on human juvenile or adult islets after exposure to PDGF-AA (50 ng/ml) for 2 days, with or without Sunitinib (2 uM) or U0126 (10 uM)co-treatment. Average percentage of BrdU+ insulin+ cells was morphometry from sectioned islets immunostained for insulin (green), glucagon (white) and BrdU (red). n = 3-6 independent experiments.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Sunitinib Malate purchased from Selleck.

    A, Tumor growth curves from the initial sunitinib drug trials, with endpoint set at 1,300 mm3 (mean ± SEM). Measurements began one week after tumor inoculation and on the day sunitinib treatment began. Subsequent experimental endpoints were set on the basis of these growth curves and their intersections with this data are shown. B, Histogram plot showing the distribution of tumor sizes at day 8 of treatment. Sunitinib-treated tumors exceeding 250 mm3 in size were identified as falling into the nonresponsive cohort. Sunitinib treatment significantly retards growth of responsive tumors.

    Cancer Res, 2017, 77(4):1008-1020 . Sunitinib Malate purchased from Selleck.

  • Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

    Sunitinib or PD98059 decreases cell proliferation in a dose-dependent manner. H295R and SW13 cells were treated with various concentration of sunitinib or PD98059 for 48 hours as indicated. Treated cells were subjected to the MTS proliferation assay. Similar experiments were repeated 3 times. Histograms represent relative % of OD490 nm absorbance (* P < .05). All data are relative multiples of expression compared with untreated cells. The data are representative of three experiments and are expressed as the mean ?SE.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

  • Autophagic activation in sunitinib- and sorafenib- but not AZD6244-treated cells. Medullary thyroid cancer-1.1 (MTC-1.1; A) and TT ( B) cells were treated with dimethyl sulfoxide (DMSO), sunitinib (50 nM), sorafenib (10 nM), AZD6244 (30 nM), or everolimus (20 nM) for 48 hours. Cell lysates were prepared, and light chain 3 (LC3)-I and -II cleaved caspase-3 protein levels were monitored by Western blotting. Reprobing against actin was per formed to ensure equal protein loading. ( C ) MTC-1.1 and TT cells were transiently transfected with autophagy protein 5 (Atg-5) small inter fering RNA. Transfection with scrambled small inter fering RNA was used as a control. After transfection, cells with and without Atg-5 knockdown were exposed to DMSO or 20 nM of everolimus for 48 hours. Cell lysates were pre- pared and LC3-I and -II protein expression levels were monitored by Western blotting. Reprobing against Atg-5 was per formed to monitor Atg-5 knockdown efficiency. Reprobing against actin was per formed to ensure equal protein.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

    Autophagy inhibition blocks the antiproliferative effects of sunitinib and sorafenib but not AZD6244. Medullary thyroid cancer–1.1 (MTC-1.1) and TT cells were transfected transiently with scrambled or autophagy protein 5 (Atg-5) small inter fering RNA. After transfection, cells with and without Atg-5 knockdown were exposed to sunitinib (50 nM), sorafenib (10 nM), and AZD6244 (30 nM) for 48 hours. Treated cells were subjected to a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay. Similar experiments were repeated 3 times. Histograms represent the relative percent of OD490 nM absorbance. The asterisk indicates significance versus scrambled small inter fering RNA–treated control ( P < .05). All data are relative multiples of expression compared to untreated cells. The data are representative of 3 experiments and are expressed as the mean ± the standard error.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

  • Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 μm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 μm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 μm.

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    2. Sunitinib downregulates HIF-1a. (A) Dose-dependent repression of HIF-1a protein level by sunitinib in HT-29. HT-29 cells were incubated under normoxic (N) or hypoxic (H) conditions in the presence of sunitinib for 24 h. HIF-1a and ARNT proteins in total cell lysates were analyzed by Western blotting. (B) Sunitinib attenuates the hypoxic induction of HIF-1 target genes. RNAs were isolated from HT-29 cells subjected to normoxia (N) or hypoxia (H) in the presence of sunitinib for 16 h. The mRNAs of HIF-1a and its target genes were analyzed by RT-PCR and autoradiography. PGK1 indicates phosphoglycerate kinase 1; PDK1, pyruvate dyhydrogenase kinase 1; CAIX, carbonic anhydrase IX. (C) Sunitinib-induced HIF-1 inhibition. Epo-enhancer and b- galactosidase reporter plasmids were co-transfected into HEK293 cells. After 16 h incubation, luciferase and b-galactosidase activities were measured. *P < .05 versus the hypoxic control.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

  • Sunitinib inhibits 50-UTR-dependent translation of HIF-1a. (A) 50 cap-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the tk promoter and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 lg per 100-mm dish) and the b-gal plasmid (4 μg). After 16 h incubation under normoxic or hypoxic conditions with sunitinib, cells were lysed and subjected to luciferase assay. *P < .05 versus the hypoxic control. (B) IRES-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the GFP gene and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 μg) and the b-gal plasmid (4 μg). *P < .05 versus the hypoxic control. (C) Sunitinib inhibits phosphorylation of Akt. After 8 h incubation under hypoxic condition with sunitinib, HT-29 cells were lysed and subjected to Western blotting. (D) Sunitinib suppresses HIF-1a in VHL-null RCC4 cells. VHL (-/-) RCC4 cells were incubated under normoxic conditions sunitinib for 8 h, and HIF-1a in total cell lysates was analyzed by Western blotting.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    Experimental layout for VEGF signaling blocking and LCMV infection in WT mice. Mice received two injections on day 0 and 3 p.i. of Abs as described in Material and Methods, or daily gavage of the VEGFR/PDGFR-inhibitor sunitinib. Inguinal LN volume on day 0 (D0) or day 8 (D8) p.i. after treatment of mice with control Ig or anti-VEGFR2, anti-VEGF-A Abs or sunitinib. Pooled from 1-2 independent experiments with 3-5 mice per treatment. D. Total HEV length on day 0 (D0) or day 8 (D8) p.i. as in C. No significant difference was found in C and D between day 8 control Ig and Ab- or inhibitor-treated values (One-way ANOVA).

    AACR Sunitinib Malate purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 M2Tnb2tqdmG|ZTDBd5NigQ>? MWHJcohq[mm2aX;uJI9nKFCGR1[tbY5lfWOnZDDCdoRWKGmwY3;ydI9z[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC3JO69VQ>? NUDjWlhiOTJ4NE[wNVk>
3T3 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rnbGlvcGmkaYTpc44hd2ZiUHzheIVt\XRvZHXybZZm\CCpcn;3eIgh\mGldH;yJIlv\HWlZXSgN3Q{KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xOSEQvF2= MVyxNlY1PjBzOR?=
3T3 MUDGeY5kfGmxbjDBd5NigQ>? MVfJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5Ihf2m2aDDJR|UxKG:oIECuNFUh|ryP M4f0SFEzPjR4MEG5
3T3 MojqT4lv[XOnIFHzd4F6 NI\nRVkzOCCvaX6= Ml3OSG1UVw>? MUfD[YxtfWyjcjDpcohq[mm2aX;uJI9nKF[HR1[gbY5lfWOnZDDoeY1idiCNRGKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB{MjFOwG0> Mo\6NVYyPjJyMEi=
NIH3T3 NUm3W4h7U2mwYYPlJGF{e2G7 MoHPNlAhdWmw M2r6T2ROW09? MluzbY5pcWKrdDDoeY1idiCNRGKgb4lv[XOnIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yMUig{txO NVfoWmxkOTZzNkKwNFg>
A549 MY\GeY5kfGmxbjDBd5NigQ>? MlT6SG1UVw>? M{DHcGlvcGmkaYTpc44hd2ZiYz3N[ZQh\GWyZX7k[Y51KEiJRj3pcoR2[2WmIHj1cYFvKEF3NEmgZ4VtdCCvaXfyZZRqd25id3n0bEBKSzVyIH;mJFIh|ryP M3HUO|E5PDN2MUS1
DU145 NYntV|BLTnWwY4Tpc44hSXO|YYm= MXXEUXNQ NYX0O3JbUW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iRGWxOFUh[2WubDDzZ4F1fGW{aX7nJJdqfGhiSVO1NEBw\iBzMDFOwG0> NYnoSG1DOTh2M{SxOFU>
KB3-1 NFL4PJlEgXSxdH;4bYMhSXO|YYm= MoDYO|IhcA>? MoDnSG1UVw>? MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdxNW6nZ3H0bZZmKEuELUOtNUBk\WyuczD3bZRpKEmFNUCgc4YhOi5|IN88US=> NXq2O|JlOTl|OUezNlI>
KBV1 NFXBPWREgXSxdH;4bYMhSXO|YYm= NFvSSYo4OiCq MUHEUXNQ Mof6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVE1odHmlb4Dyc5RmcW5vZYjwdoV{e2mwZzDLRnYyKGOnbHzzJJdqfGhiSVO1NEBw\iB2LkGg{txO MmW3NVk{QTd|MkK=
A375 NWLyTJhmS3m2b4TvfIlkKEG|c3H5 NUf4SYtiPzJiaB?= NF7xVZFFVVOR NHm1WoFKSzVyPUWuOEDPxE1? NXzQSJZIOTl4NUS0NFg>
RS4-11 MnXzSpVv[3Srb36gRZN{[Xl? MWGyJIg> NGjjZ4VKdmirYnn0bY9vKG:oIF\MWFMh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODl7IN88US=> MUSxPVY2PDRyOB?=
RS4-11 M13WNWZ2dmO2aX;uJGF{e2G7 MYqyJIg> NWOweW9mUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yM{Sg{txO MX:xPVY2PDRyOB?=
Sf9 NVWzXY9bU2mwYYPlJGF{e2G7 NVTRd4YxOzBibXnu MojqTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIG\FS2ZTKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNE4yQDVizszN NUX5[JNWOTl6NUSwOVE>
Ba/F3 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrFXVY4OiCq M3TCVmlEPTB;MT6yJO69VQ>? Ml2yNlAyOTdyMES=
BaPTC2 M2\Ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfwO|IhcA>? MYHJR|UxRTBwMkKg{txO MorCNlAyOTdyMES=
Sf9 MmH6SpVv[3Srb36gRZN{[Xl? MXuxJIg> M13KPWROW09? M{XTemlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSHnzMZRi\2enZDDSSXQh\XiycnXzd4VlKHerdHigTWM2OCCxZjCxMlMh|ryP MmDrNlAyOTdyMES=
H4 MX3DfZRwfG:6aXOgRZN{[Xl? NEnwbosyOCEQvF2= MnrqWI95cWOrdImgbY4hcHWvYX6gTFQh[2WubIO= NGGyXFEzODN3MEiwOi=>
SF-539 MWXLbY5ie2ViQYPzZZk> NGXzPFg{OzNizszN Mle2OlAhdWmw NFXXT|hFVVOR MVnJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGyMlIh|ryP NHfpPFQzODRyM{ewNC=>
U251 NUTaSYU{U2mwYYPlJGF{e2G7 MmfrN|M{KM7:TR?= NE\hTJc3OCCvaX6= MXnEUXNQ NUXLTWFPUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxPE46KM7:TR?= MlnXNlA1ODN5MEC=
A431 MmLrT4lv[XOnIFHzd4F6 MV7Jcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEzNjJizszN NWT3SnlbOjB3NUiwO|I>
A431 MkjHT4lv[XOnIFHzd4F6 NWXwRlNNUW6qaXLpeIlwdiCxZjDWSWdHWjJiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyQC57IN88US=> NX3sTZpmOjB3NUiwO|I>
HepG2 M2jkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrxUog4OiCq NWrJXYxzUUN3ME2zMlgyKM7:TR?= Mmf1NlA2PzB3Mk[=
Kasumi-1 NXzsTXc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mwd|czKGh? MWnJR|UxRTBwMEG2JO69VQ>? M3[5d|IxPTdyNUK2
RS4-11 NXPNbVdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXG3NkBp M2T3PWlEPTB;MTFOwG0> MVeyNFU4ODV{Nh?=
THP1 NIT5VoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOxeolPPzJiaB?= MmnyTWM2OD1yLkWg{txO NEnhNJIzODV5MEWyOi=>
Kasumi-1 NVX2WVdCTnWwY4Tpc44hSXO|YYm= MVXJcohq[mm2aX;uJI9nKGNvS3n0JIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFE2KM7:TR?= MW[yNFg{OzB|OR?=
A549 NHjpOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfwNVYhcA>? MXTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy| NYrzNnoxOjF2NUC0OlM>
HL60 NVLRT2h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuxOkBp MUXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy| MofnNlE1PTB2NkO=
HUVEC NYjBfWZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf0NVYhcA>? NI\SV5ZKdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIEKuO|Uh|ryP M4nVV|IyPDVyNE[z
HUVEC NHq4N2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ewbFE3KGh? M1rHWWlvcGmkaYTpc44hd2ZiYl\HSk1qdmS3Y3XkJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiND6wOEDPxE1? MlztNlE1PTB2NkO=
IM9 MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjUOJcyOTZiaB?= NXflXFNCSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTW06KGOnbHzz MYOyNVQ2ODR4Mx?=
K562 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:xOkBp MnXORY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\Wyucx?= MXKyNVQ2ODR4Mx?=
MDA-MB-231 NV3HbYZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16w[|E3KGh? NYrIbFRWSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\Wyucx?= MX6yNVQ2ODR4Mx?=
H460 MWTDfZRwfG:6aXOgRZN{[Xl? MmP4O|IhcA>? MX7JR|UxRTJwNzFOwG0> NHrGdWkzOTZ{MUi4NC=>
SMMC7721 MXrDfZRwfG:6aXOgRZN{[Xl? NUnZ[2JlPzJiaB?= MlnmTWM2OD14LkS3JO69VQ>? MWeyNVYzOTh6MB?=
WI38 M{fBUGN6fG:2b4jpZ{BCe3OjeR?= M2npbFczKGh? NV3sS291UUN3ME24MlU3KM7:TR?= M1nrR|IyPjJzOEiw
HEK293 NED5SW1McW6jc3WgRZN{[Xl? MlTINVAxKG6P MYixJIg> NVzwTodN\G:nczDuc5QhcW6qaXLpeEBXTUeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kB1gXKxc3nu[UAyOTd3IILld4llfWVib36gWmVITlJ{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHN? MlXUNlE5QDV{OEe=
HUVEC M2GwWWZ2dmO2aX;uJGF{e2G7 NU\HOWVHOSEQvF2= M1;T[VI1KGh? M1T4c2FvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKF[HR1[tbY5lfWOnZDDj[YxtKG2rZ4LheIlwdg>? MoDBNlE6PjN|MEW=
HUVEC M1PiOmZ2dmO2aX;uJGF{e2G7 MUGxJO69VQ>? M3e5bVEhcA>? MWnJcohq[mm2aX;uJI9nKEWUSzDwbI9{eGixconsZZRqd25iYYSgWIhzOjB{L2T5dlIxPCCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> MUmyNVk3OzNyNR?=
HUVEC MYXGeY5kfGmxbjDBd5NigQ>? M1GxVlEh|ryP MU[xJIg> Ml;mTY5pcWKrdHnvckBw\iCnTl;TJJBpd3OyaH;yfYxifGmxbjDheEBU\XJvMUG3NkBqdiCYRVfGMZN1cW23bHH0[YQhUFWYRVO= M4TvRlIyQTZ|M{C1
HUVEC MmSwT4lv[XOnIFHzd4F6 MnjzNUDPxE1? NVTQOJB7OSCq M4GxbmlvcGmkaYTpc44hd2ZiVlXHSnIzKHCqb4PwbI9zgWyjdHnvckBifCC2eYKtNVE4PSCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> MkPHNlE6PjN|MEW=
HUVEC Mn3VSpVv[3Srb36gRZN{[Xl? M3vOSFEh|ryP M2PrNlEhcA>? M4DEbYRw\XNibn;0JIlvcGmkaYSgRWtVKHCqb4PwbI9zgWyjdHnvckBifCCVZYKtOFc{KGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> MmnuNlE6PjN|MEW=
HL60 NWXWcIJFS3m2b4TvfIlkKEG|c3H5 M4[4OFUxKM7:TR?= M3\NSlQ5KGh? NIqzSlVFVVOR NXzrPYJWUUN3ME2xOU42KM7:TR?= NG\DXmozOjBzOUG4PC=>
K562 NFvJdnREgXSxdH;4bYMhSXO|YYm= MX[1NEDPxE1? M164[|Q5KGh? NFy5bZdFVVOR NFiwXpJKSzVyPUKxMlkh|ryP MVmyNlAyQTF6OB?=
PC3 MUXDfZRwfG:6aXOgRZN{[Xl? MlzUOVAh|ryP MmfBOFghcA>? NWj6PHZ4TE2VTx?= NV;sN2Z1UUN3ME2yOU4yKM7:TR?= MVyyNlAyQTF6OB?=
SF-539 MmLlT4lv[XOnIFHzd4F6 NFSwUHE{OzNizszN M{nyUlYxKG2rbh?= NEDhSGpKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTD0fZJwe2mwZTDrbY5ie2ViYXP0bZZqfHliaX6gVGRITi2EQj3zeIlufWyjdHXkJIh2dWGwIGPGMVU{QSClZXzsd{B4cXSqIFnDOVAhd2ZiMUKuNkDPxE1? MYCyNlIxPDd2MR?=
HAEC NWnMRYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKxNFAh|ryP NGTGe4I4OiCq NHTsbGxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjBSWMh[2WubIOg[ZhxemW|c3nu[{BXTUeIUjD3bZRpKEmFNUCgc4YhOC5zIN88US=> M1TxcVIzPDR2Nke5
HT-29 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\pfVExOCEQvF2= NYTOSpFTPzJiaB?= MoLYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDlfJBz\XO|aX7nJHZGT0[UIIfpeIghUUN3MDDv[kAxNjN|IN88US=> MXmyNlQ1PDZ5OR?=
MV4-11 NUHIdYJUS3m2b4TvfIlkKEG|c3H5 NVHwZXVzPzJiaB?= NEjZcZVKSzVyPUCuNFA{KM7:TR?= MnzPNlI1PTJ3MUi=
HepG2 NVrRNYVFS3m2b4TvfIlkKEG|c3H5 NYXmWIFiPDhiaB?= MkXrTWM2OD1zMz6yOEDPxE1? MYqyNlQ5OzZyOB?=
PC9 MoLuR5l1d3SxeHnjJGF{e2G7 NIjoSZY1QCCq M{DLTWlEPTB;MUCuPVch|ryP NE\4V|czOjR6M{[wPC=>
CAKI-1 M2\RV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPJNVAxKM7:TR?= MV[0PEBp M{H1W2ROW09? M3f2TGdKPTB;MD62N{DPxE1? M2OyXVIzPTZyNkK3
EKVX M3\WSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLEelYyODBizszN NEDFcHc1QCCq MmXUSG1UVw>? MW\HTVUxRTdwOTFOwG0> NWDXTXJMOjJ3NkC2Nlc>
MCF7 NXPDdIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P1PVExOCEQvF2= MWS0PEBp M3XLfGROW09? NULt[YtOT0l3MU2yJO69VQ>? MnXrNlI2PjB4Mke=
MDA-MB-435 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\md|NpOTByIN88US=> M{fKbFQ5KGh? NHHTS29FVVOR M4rGcGdKPTJ;MjFOwG0> NIm4[okzOjV4ME[yOy=>
OVCAR3 NGHj[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHYNVAxKM7:TR?= MUi0PEBp MmC5SG1UVw>? MXjHTVU{RTNwMjFOwG0> MXeyNlU3ODZ{Nx?=
SNB19 NXHwb4JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGSyWpgyODBizszN MY[0PEBp NFHMeYJFVVOR MWjHTVU1RTFyIN88US=> M4PZUlIzPTZyNkK3
SW620 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PjbVExOCEQvF2= NUPze3Q3PDhiaB?= NUXYO2U2TE2VTx?= M2rLVGdKPTV;MT6zJO69VQ>? M3zZTFIzPTZyNkK3
TK10 NXHSNIFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLkXY4yODBizszN NF;lVmE1QCCq MULEUXNQ M{DWWmdKPTZ;Nj6zJO69VQ>? M1XGPFIzPTZyNkK3
UACC257 M1\YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K2VlExOCEQvF2= Mn3pOFghcA>? M4\hXmROW09? NFPRZmRIUTV5PUSg{txO MnTlNlI2PjB4Mke=
HAEC NUL0XVlSS3m2b4TvfIlkKEG|c3H5 NYTPbnFvOTByIN88US=> NIqydnE4OiCq MXXEUXNQ M{D3cmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KF[HR1\SJIV5eHKnc4PpcochUEGHQzD3bZRpKEmFNUCgc4YhOC5zIN88US=> MnzZNlMyOzF3NEG=
HT-29 Mki5R5l1d3SxeHnjJGF{e2G7 MUWxNFAh|ryP MkDnO|IhcA>? MVrEUXNQ NXnxO3pFS3m2b4TvfIlkcXS7IHHnZYlve3RiVlXHSnIh\XiycnXzd4lv\yCqdX3hckBJXC1{OTDj[YxteyC5aYToJGlEPTBib3[gNE4{OyEQvF2= NXraVnhQOjNzM{G1OFE>
HCT116 M2PrNWZ2dmO2aX;uJGF{e2G7 MonpNlQhcA>? MVLEUXNQ MnrxRY51cW2rZ4LheI9zgSCjY4Tpeol1gSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygcYloemG2aX;u NFGzSnozOzF3M{KwNC=>
HUVEC M4DlZmZ2dmO2aX;uJGF{e2G7 MVSyJO69VQ>? MVKxPEBp NG[2fohFVVOR NFrIU2hCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQ4OgeY5l\XJiaInwc5hq[yClb37kbZRqd25iYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXLlJIZwem2jdHnvci=> MYKyN|E2OzJyMB?=
ACHN NH\uR4JEgXSxdH;4bYMhSXO|YYm= M33YO|Yh\A>? NID1NVBKSzVyPUKuOUDPxE1? NH7xcWEzOzN4MEGwOC=>
A498 M1rvUWN6fG:2b4jpZ{BCe3OjeR?= NYnqTGtbOTByIN88US=> MnLHO|IhcA>? M{nZWGROW09? NFfNRZBKSzVyPUSuN{DPxE1? NYSwN2M2OjN2OEm2NlY>
HUVEC NVmzN|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\rVJp5OyEQvF2= NYjSdVlkOjRiaB?= MnTQSG1UVw>? Mn\jRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgeJVj\SCob4LtZZRqd25id3n0bEBGSzVyIH;mJFAvPjR3IN88US=> M1naVlI{PTh|OUGx
HUVEC M1LqU2tqdmG|ZTDBd5NigQ>? M3P1blIxOCEQvF2= MYfEUXNQ MWLJcohq[mm2aX;uJI9nKF[HR1\SNkBxcG:|cHjvdplt[XSrb36gbY4h\3Kxd4ToJIZi[3Sxcj3zeIlufWyjdHXkJGhWXkWF MYKyN|U5OzlzMR?=
HUVEC Mn;DT4lv[XOnIFHzd4F6 NULZSXMxOjByIN88US=> NYLvOIlNTE2VTx?= NHHrfVJKdmirYnn0bY9vKG:oIG\FS2ZTOSCyaH;zdIhwenmuYYTpc44hcW5iZ4Lve5RpKG[jY4Tvdk1{fGmvdXzheIVlKEiXVlXD MWKyN|U5OzlzMR?=
A549 NIXIOJBEgXSxdH;4bYMhSXO|YYm= MYS3NkBp M1ftSmROW09? NHTBU3JKSzVyPUKuOFQh|ryP Ml\NNlM3ODJ2NEG=
HCT116 MlfIR5l1d3SxeHnjJGF{e2G7 MVO3NkBp M1uzbWROW09? NFH0bFhKSzVyPUSuO|Eh|ryP Mn3PNlM3ODJ2NEG=
MCF7 M{ewNGN6fG:2b4jpZ{BCe3OjeR?= NYDSNYtJPzJiaB?= MXrEUXNQ MmrSTWM2OD14LkK5JO69VQ>? MVeyN|YxOjR2MR?=
BGC NFPUTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XhbVczKGh? NFnqdnZFVVOR MlruTWM2OD12Lke4JO69VQ>? MX:yN|k6QTB2MB?=
BxPC3 M2PaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfXO|c4OiCq NY\iUWhSTE2VTx?= MkTrTWM2OD1|Lk[zJO69VQ>? MWCyN|k6QTB2MB?=
HT-29 M3\RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYK3NkBp NX33cWo1TE2VTx?= NVL5VWNMUUN3ME2xMlQ4KM7:TR?= NH60ZVYzOzl7OUC0NC=>
T24 M1nvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDlO|IhcA>? NUnQdmtvTE2VTx?= M3T3d2lEPTB;Mj60OEDPxE1? NWPIeotwOjN7OUmwOFA>
4T1 NVnNOZE6S3m2b4TvfIlkKEG|c3H5 NWG3NoJjPzJiaB?= Mof0SG1UVw>? M3nlXWlEPTB;MD6wNVYh|ryP M{ewd|I1QDlyNkWy
MCF7 NIHpOWFEgXSxdH;4bYMhSXO|YYm= MWK3NkBp NUTt[ok5TE2VTx?= MYTJR|UxRTBwMEK3NUDPxE1? MUeyOFg6ODZ3Mh?=
MCF7 MnrRR5l1d3SxeHnjJGF{e2G7 NInQ[Iw4OiCq M{\PfGROW09? NETEeFNKSzVyPUCuNFI6OyEQvF2= MmLmNlQ5QTB4NUK=
MDA-MB-231 MXHDfZRwfG:6aXOgRZN{[Xl? MUe3NkBp Mk\OSG1UVw>? NV3aVYVUUUN3ME2wMlAzOjNizszN M2\sO|I1QDlyNkWy
MDA-MB-435 M1vmPWN6fG:2b4jpZ{BCe3OjeR?= NVHWcGQyPzJiaB?= NWT5OpByTE2VTx?= NHTrPG1KSzVyPUCuNFA6PyEQvF2= MVGyOFg6ODZ3Mh?=
MDA-MB-468 NIHmc3FEgXSxdH;4bYMhSXO|YYm= NHjINI44OiCq M{DidGROW09? MVfJR|UxRTBwMEC2NUDPxE1? MXuyOFg6ODZ3Mh?=
A431 MVrLbY5ie2ViQYPzZZk> NEG1fZgyOCEQvF2= NWnSbZU1OSCq NELHR|BFVVOR MWrJcohq[mm2aX;uJI9nKEWJRmKge4l1cCCLQ{WwJI9nKDBwMUeyNUDPxE1? MYCyOFg6ODZ3Mh?=
SH-SY5Y MYfLbY5ie2ViQYPzZZk> NF6xXJoyOCEQvF2= M3rUeVEhcA>? MV;EUXNQ NVzMPWpUUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGge4l1cCCLQ{WwJI9nKDBwMEizNUDPxE1? M3L2c|I1QDlyNkWy
U251 M{ToTmtqdmG|ZTDBd5NigQ>? MUmxNEDPxE1? Ml\DNUBp MWDEUXNQ MYXJcohq[mm2aX;uJI9nKF[HR1\SNkB4cXSqIFnDOVAhd2ZiMD6wNVg6KM7:TR?= MYiyOFg6ODZ3Mh?=
Bel7402 NV\KXnNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK3NkBp NXPoSWFzTE2VTx?= M4rrcmlEPTB;Mj62O{DPxE1? MmjnNlQ6ODR7NkG=
HK2 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHXO|IhcA>? NYLqcG5bTE2VTx?= NICxWnFKSzVyPUWuPFUh|ryP NF;v[|gzPDlyNEm2NS=>
LO2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7jT4w4OiCq NXn1R5FwTE2VTx?= NYPXd2N5UUN3ME2xPU46OyEQvF2= NY\hbVJ5OjR7MES5OlE>
MV4-11 NXq5PI5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC3OFghcA>? Mo[ySG1UVw>? MVXJR|UxRTBwMECzJO69VQ>? M{GxPFI1QTB2OU[x
NCI-H3122 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HlSFczKGh? Ml7PSG1UVw>? NVXVeY5WUUN3ME2wMlg{KM7:TR?= Ml3TNlQ6ODR7NkG=
NCI-H460 M3;0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PEXlczKGh? NE\3NlJFVVOR NVHNXJczUUN3ME20MlMyKM7:TR?= NHnvVnAzPDlyNEm2NS=>
NCI-H526 NHviVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO3O|IhcA>? M3rJN2ROW09? MkjTTWM2OD1zLkCxJO69VQ>? MViyOFkxPDl4MR?=
TT M{O3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL2PJc4OiCq NFTMUI5FVVOR M2roXWlEPTB;MD6wOEDPxE1? MXWyOFkxPDl4MR?=
EoL-1-cell NUnze21OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHKZodKSzVyPUGuOlQheE1? NHjCV|dUSU6JRWK=
MV-4-11 NEPoOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXNTWM2OD1{N{KgdG0> NUn6dmF1W0GQR1XS
NOS-1 NHvrfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF3LkOgcm0> M1LY[nNCVkeHUh?=
CGTH-W-1 NVnqdW1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\XeIhKSzVyPUOwMlk1KG6P NWrOUXRDW0GQR1XS
MONO-MAC-6 M{f2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLwbHNKSzVyPUOzMlghdk1? MlPBV2FPT0WU
ALL-PO NFPFeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTYRXJKSzVyPUe5Mlg6KG6P M4jjWXNCVkeHUh?=
NKM-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn1ZpVKSzVyPUm4MlUzKG6P M4LBRXNCVkeHUh?=
KM12 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTN3MD6xOEBvVQ>? MkXPV2FPT0WU
TE-15 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L3emlEPTB;NUC3MlYyKG6P NUHaV5BWW0GQR1XS
697 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj2T5BKSzVyPU[xOE4zPSCwTR?= MWTTRW5ITVJ?
MOLT-16 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH3RWZKSzVyPU[zNU4{OiCwTR?= NF33PWFUSU6JRWK=
GB-1 NF6zT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7CWIhPUUN3ME23NVAvOjNibl2= M17WXHNCVkeHUh?=
TE-12 M3rFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvIS45KSzVyPUiwOE42PSCwTR?= NVfzToIzW0GQR1XS
ES6 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlyzTWM2OD17OEGuNFYhdk1? M1HpfXNCVkeHUh?=
LC-2-ad Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK1eWMyUUN3ME2xMlEyPDB5IN88US=> NEHwPHlUSU6JRWK=
BL-70 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfYTWM2OD1zLkGxPFQ3KM7:TR?= Mn7QV2FPT0WU
ETK-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\J[oFEUUN3ME2xMlI5PThizszN NFPpUVVUSU6JRWK=
A4-Fuk MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwM{SxOFEh|ryP MknMV2FPT0WU
OCI-AML2 NVPwOFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILYd5dKSzVyPUGuN|Y5PTFizszN MX3TRW5ITVJ?
SIG-M5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT1RWdKSzVyPUGuN|cxODlizszN MoG5V2FPT0WU
NCI-SNU-16 NXHDUWFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\YNW83UUN3ME2xMlQ3PDh4IN88US=> NUTjXVExW0GQR1XS
PSN1 NH;GeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nkOGlEPTB;MT61NFY4PiEQvF2= NYnvW5BSW0GQR1XS
SR MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PJUWlEPTB;MT61OFU4OiEQvF2= Ml\iV2FPT0WU
A3-KAW NUHRd25HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\ZSI1oUUN3ME2xMlYzPTR4IN88US=> NGjqRWtUSU6JRWK=
KS-1 NFHYUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zOZmlEPTB;MT62PVI1PyEQvF2= Ml;aV2FPT0WU
CTV-1 NH;Eb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP5XGY2UUN3ME2xMlczPzVzIN88US=> M2jodXNCVkeHUh?=
LB1047-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTMO5VKSzVyPUGuPFE3OjRizszN NGP3U29USU6JRWK=
EMG-01 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3mW|NvUUN3ME2xMlg{PTZ|IN88US=> NFn1Z|lUSU6JRWK=
TE-11 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fPRWlEPTB;MT64N|k5PSEQvF2= MofrV2FPT0WU
CMK NHWwPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zCXmlEPTB;MT65OVUyPyEQvF2= MYrTRW5ITVJ?
NB1 M3\jO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwOU[xNVch|ryP NFXFN3VUSU6JRWK=
HAL-01 NIP1VVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHqTWM2OD1{LkC1PVQ3KM7:TR?= M1X1XXNCVkeHUh?=
DEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TybmlEPTB;Mj6wPFQ5OiEQvF2= NH:1RVFUSU6JRWK=
RL95-2 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3OTWM2OD1{LkGxNVM4KM7:TR?= NVvvOpZrW0GQR1XS
KARPAS-299 NEOzTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;GTWM2OD1{LkGxN|E{KM7:TR?= NUf4ZVFtW0GQR1XS
EW-16 NFzTWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTnTWM2OD1{LkGzOVA5KM7:TR?= M3HxTnNCVkeHUh?=
RS4-11 MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvPTWM2OD1{LkG3PVI1KM7:TR?= Mny1V2FPT0WU
BB30-HNC NV;VRm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\DTWM2OD1{LkKyN|c2KM7:TR?= NGDYTY9USU6JRWK=
DOHH-2 NFnTNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jJN2lEPTB;Mj6zN|Q{OSEQvF2= MWXTRW5ITVJ?
RPMI-8402 MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHtTJNKSzVyPUKuN|M3OThizszN MWfTRW5ITVJ?
BV-173 MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7uTWM2OD1{LkOzOlYh|ryP MXfTRW5ITVJ?
TE-10 M1[2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJwM{SzPFQh|ryP NU\OSWdOW0GQR1XS
TE-8 NG\PfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vJWmlEPTB;Mj6zO|A{QCEQvF2= NH23XIxUSU6JRWK=
K052 NET0U3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj3WHNKSzVyPUKuOFAzODJizszN Mlu2V2FPT0WU
KARPAS-45 NHnEOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HmZ2lEPTB;Mj60PVQ1PiEQvF2= NYrOVYVWW0GQR1XS
SK-NEP-1 NUHPdHA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjZO3A4UUN3ME2yMlYxOjN5IN88US=> NYjnO3ZbW0GQR1XS
KGN MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJwNkCzN|kh|ryP Mlm0V2FPT0WU
ML-2 MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfzTWM2OD1{Lk[zOVEzKM7:TR?= NFjze3JUSU6JRWK=
LAMA-84 NHTwVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDSNphCUUN3ME2yMlY6PTR3IN88US=> NVW0UpExW0GQR1XS
LXF-289 NXnzUpJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTETWM2OD1{LkeyPVg6KM7:TR?= MmPCV2FPT0WU
A101D NGTVZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwN{izNFQh|ryP MmjEV2FPT0WU
KY821 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLRWFROUUN3ME2yMlc6PzV6IN88US=> MkexV2FPT0WU
ES4 NVrwWlU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi4bFZKSzVyPUKuPFA3OjhizszN NHzyNmFUSU6JRWK=
SCC-3 M2LHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDCWIdKSzVyPUKuPFI5QTFizszN NUTFVWJPW0GQR1XS
NALM-6 NGG2UWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ToOGlEPTB;Mj65NFQ4OyEQvF2= MljFV2FPT0WU
BL-41 M4T1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVviSnFGUUN3ME2yMlkyOjJ{IN88US=> NWf3PFRLW0GQR1XS
OPM-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNwMEW5OVQh|ryP MomxV2FPT0WU
SF126 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVziUpJoUUN3ME2zMlA3OTl6IN88US=> NHfDWYdUSU6JRWK=
BE-13 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNwMkOxNVEh|ryP NGO2OlhUSU6JRWK=
SF268 NFSxZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITKTItKSzVyPUOuN|I5PjlizszN NWDOV3pMW0GQR1XS
MOLT-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rlemlEPTB;Mz6zPVg{QCEQvF2= MoTXV2FPT0WU
PF-382 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNwNES1O{DPxE1? M4O5W3NCVkeHUh?=
HEL NYny[HdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnmW4lqUUN3ME2zMlQ5ODB3IN88US=> NFy0XHZUSU6JRWK=
RPMI-6666 M3\Kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHkTWM2OD1|LkW0NVcyKM7:TR?= NY\nNJlGW0GQR1XS
QIMR-WIL MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNwNkOzPVEh|ryP MlvqV2FPT0WU
ATN-1 M{nz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nwdWlEPTB;Mz62O|EyPCEQvF2= Mo[2V2FPT0WU
BB49-HNC M4ezT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK5TWM2OD1|LkewOVA5KM7:TR?= MnfsV2FPT0WU
HCE-4 NIDGfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNwN{i2OFIh|ryP M3n0[XNCVkeHUh?=
SK-LMS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXTSGo{UUN3ME2zMlg{OzN6IN88US=> NVG1SZRkW0GQR1XS
MS-1 NWrtS4hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTNwOEO3O|gh|ryP M2LhV3NCVkeHUh?=
JAR M4frbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjVRnVsUUN3ME2zMlk5QDN{IN88US=> NGLjUVdUSU6JRWK=
KE-37 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWxTWM2OD12LkC2NVU5KM7:TR?= NH\OUIVUSU6JRWK=
LB996-RCC NXzSNZpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vlfGlEPTB;ND6xNlE3QCEQvF2= Mnf4V2FPT0WU
HH MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEToU|BKSzVyPUSuNlA6OTRizszN NHe5e|RUSU6JRWK=
HL-60 NWOxfnh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrpTWM2OD12LkKxNFY2KM7:TR?= MXXTRW5ITVJ?
HOP-62 NFHpSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTRwM{O1NkDPxE1? M1\h[XNCVkeHUh?=
NOMO-1 NWfYVFZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwM{O2PVkh|ryP M4\lNHNCVkeHUh?=
DU-4475 NELtWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfuOYNTUUN3ME20MlM3PzJ7IN88US=> NYnHfpdnW0GQR1XS
LC4-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXJOYlKSzVyPUSuN|gxPyEQvF2= NF3qOmRUSU6JRWK=
MC116 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XQS2lEPTB;ND60N|A5OSEQvF2= NF3O[nNUSU6JRWK=
SW982 NFe0OG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j4R2lEPTB;ND61OVMxPyEQvF2= Ml33V2FPT0WU
SK-N-DZ M2DxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjWV3lKSzVyPUSuOlcxQTlizszN NE\YN5VUSU6JRWK=
EW-1 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy0eHF7UUN3ME20MlY4QTFzIN88US=> MYnTRW5ITVJ?
SU-DHL-1 M3vDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTRwOECxO|Qh|ryP NYrtVGdHW0GQR1XS
L-363 MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjvWW9KSzVyPUSuPFA3OjFizszN NW[xVIF5W0GQR1XS
OS-RC-2 NIjXd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXvTWM2OD12Lki3N|Eh|ryP M1vwNnNCVkeHUh?=
HD-MY-Z NWS1d2I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;vTWM2OD13LkG3N|AyKM7:TR?= MUDTRW5ITVJ?
MHH-PREB-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTVwM{KzNVIh|ryP NHKwR3RUSU6JRWK=
HC-1 NX3y[IV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTVwNEOyPVEh|ryP NW\4VWdOW0GQR1XS
SK-MM-2 NFHnV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHlfYhNUUN3ME21MlQ4QDJizszN MX\TRW5ITVJ?
SH-4 M17SXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTaN2o{UUN3ME21MlQ5OzdizszN NUW3OlBSW0GQR1XS
MHH-CALL-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\OcmlEPTB;NT63OlcyQSEQvF2= MYjTRW5ITVJ?
KG-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\0S2lEPTB;Nj6wNlg4QCEQvF2= Mke4V2FPT0WU
J-RT3-T3-5 NX;PZY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnCU2ZKSzVyPU[uNFc6ODlizszN NUnjUY9YW0GQR1XS
MMAC-SF NHL6b5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T4RWlEPTB;Nj6xNFk1QSEQvF2= MWTTRW5ITVJ?
IST-SL2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTZwMUK1NVkh|ryP M37lbXNCVkeHUh?=
SW954 NVrwVIVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m0VGlEPTB;Nj6yO|UyPyEQvF2= NV3yN5lTW0GQR1XS
HDLM-2 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGzTWM2OD14LkOyNVA6KM7:TR?= MWPTRW5ITVJ?
ST486 NHv2c2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX2TWM2OD14LkO0O|Eh|ryP MYjTRW5ITVJ?
DG-75 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTZwNEOwOlkh|ryP M3flb3NCVkeHUh?=
EW-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZwNEOyNFch|ryP M33vTnNCVkeHUh?=
8-MG-BA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv2cWE3UUN3ME22MlUyPTB5IN88US=> MkjwV2FPT0WU
GT3TKB MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfPcopKSzVyPU[uOlA4PjNizszN NWm3clM2W0GQR1XS
KU812 NGXj[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\VTWM2OD14Lk[5OFIh|ryP MXvTRW5ITVJ?
CESS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrRTWM2OD15LkGwOFM5KM7:TR?= MlPHV2FPT0WU
BC-1 NH:1b2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD0WmxKSzVyPUeuNlQ5OTJizszN NXPXV3lqW0GQR1XS
MZ1-PC M1m3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzBPVlNUUN3ME23MlMxOzh7IN88US=> MUTTRW5ITVJ?
NCI-H82 NXLNWpVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjTRYNKSzVyPUeuN|c5PSEQvF2= M3TBUnNCVkeHUh?=
NCI-H1355 Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zTbWlEPTB;Nz60OVgxPCEQvF2= MofpV2FPT0WU
RPMI-8226 M3zsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTdwNUC3N|kh|ryP NGDtSJZUSU6JRWK=
ARH-77 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGyV3dKSzVyPUeuOVM2QTdizszN MUPTRW5ITVJ?
MN-60 NHfjWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTdwNUSwPFgh|ryP M2rZb3NCVkeHUh?=
IMR-5 M1rld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTkSYdlUUN3ME23NFU1QDd4IN88US=> MXXTRW5ITVJ?
KARPAS-422 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX36ephlUUN3ME23MlU4OjB4IN88US=> M2nEWXNCVkeHUh?=
CA46 M{\hSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHYVotKSzVyPUeuOVgxOTJizszN Mo\CV2FPT0WU
SJSA-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnniTWM2OD15Lk[2NFYyKM7:TR?= NVz5e5Q5W0GQR1XS
no-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjRTWM2OD15Lke3OVU4KM7:TR?= Mn7wV2FPT0WU
IST-SL1 NWG1fJpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRThwMEK0NVch|ryP NFn2OmdUSU6JRWK=
NCI-H209 M{DaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonHTWM2OD16LkGxOlUzKM7:TR?= NHrJZ21USU6JRWK=
TALL-1 MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTlTWM2OD16LkG4N|g1KM7:TR?= NYjDOGdTW0GQR1XS
KMOE-2 M3LTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljmTWM2OD16LkG5OFIh|ryP M4\0ZnNCVkeHUh?=
HCC1599 M{DNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLTZlV1UUN3ME24MlE6QTh5IN88US=> M1XU[HNCVkeHUh?=
CI-1 NV7TOGM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrRdZJKSzVyPUiuNlA1OTFizszN M1LNRXNCVkeHUh?=
NCI-H1304 MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRThwMkC2OlEh|ryP MX7TRW5ITVJ?
Daudi NGDRbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjUd3lOUUN3ME24MlI{PTR4IN88US=> MlfFV2FPT0WU
CPC-N Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmwTWM2OD16LkK5NVk6KM7:TR?= MUDTRW5ITVJ?
MC-CAR MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m1dmlEPTB;OD6zN|U5KM7:TR?= NEO1TlRUSU6JRWK=
SW872 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuyTWM2OD16LkO0O|U5KM7:TR?= NVr0[oxWW0GQR1XS
OVCAR-4 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe3OphiUUN3ME24MlUxOzVzIN88US=> NHHTeHRUSU6JRWK=
OCUB-M NH;NS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjPTVlzUUN3ME24MlU3PTB6IN88US=> NYq5VJdKW0GQR1XS
SK-PN-DW MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLVOmVKSzVyPUiuOlA6QDVizszN MWrTRW5ITVJ?
NCCIT NIrxVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP3TWM2OD16LkexO|Q2KM7:TR?= MmrmV2FPT0WU
NCI-H1648 M2HLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPNTWM2OD17LkGzPFM1KM7:TR?= NEnFOVBUSU6JRWK=
COR-L279 NEWz[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHoW5ZKSzVyPUmuN|kxQSEQvF2= NHXne5JUSU6JRWK=
LS-123 NET1O|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXK[WNKSzVyPUmuOlgyPjFizszN M{HadXNCVkeHUh?=
LP-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\4NWRkUUN3ME25Mlc5ODh|IN88US=> MoTXV2FPT0WU
NB13 M4HDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M161OmlEPTB;OT63PVk6PCEQvF2= MnnpV2FPT0WU
ONS-76 M37kXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf6d4tKSzVyPUmuPFExOTZizszN NXXPWHoxW0GQR1XS
VA-ES-BJ MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfQXFdKSzVyPUmuPVk6OzNizszN NIL4N2hUSU6JRWK=
GR-ST NV3RfnRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFyLkKyNFch|ryP NU\CbFRPW0GQR1XS
ES1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLzVYdNUUN3ME2xNE4zQTh2IN88US=> NUDnUZRJW0GQR1XS
NB14 M4PMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rsXmlEPTB;MUCuPVI4PyEQvF2= MmriV2FPT0WU
Ramos-2G6-4C10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfrUY9LUUN3ME2xNU4zPjVizszN MWHTRW5ITVJ?
RXF393 NGfvc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInvNWhKSzVyPUGxMlQ5OzRizszN MnX4V2FPT0WU
NCI-H2107 NVmwfW9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLCO5FKSzVyPUGxMlU6QDRizszN M1fOTnNCVkeHUh?=
K562 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXDbXNKUUN3ME2xNU45PzB{IN88US=> MW\TRW5ITVJ?
LOUCY NXLQfpRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjubIJKSzVyPUGxMlk5PzVizszN M3nRVHNCVkeHUh?=
TGBC1TKB MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS5cpdKSzVyPUGyMlAxOiEQvF2= NGnrcWpUSU6JRWK=
COLO-320-HSR MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\4TWM2OD1zMj6xOVY2KM7:TR?= NHfxNVhUSU6JRWK=
K5 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTpUnZKSzVyPUGyMlI6QDVizszN MWrTRW5ITVJ?
BC-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF{LkS2OVEh|ryP NVuwe3JSW0GQR1XS
REH MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS0O4UzUUN3ME2xNk43PDl6IN88US=> NWPybldFW0GQR1XS
NEC8 NVjXSpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF{Lk[4PFch|ryP NHrtc5lUSU6JRWK=
IST-MEL1 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXITWM2OD1zMj64Olk1KM7:TR?= NED0ZlJUSU6JRWK=
NCI-H128 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D6SWlEPTB;MUOuNFczOyEQvF2= NXHlPHduW0GQR1XS
NCI-H1694 NHjLZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r6WmlEPTB;MUOuNVE1PCEQvF2= MWPTRW5ITVJ?
TGW NYrwOXdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvnTWM2OD1zMz6zNlc3KM7:TR?= NGXqPWZUSU6JRWK=
NCI-SNU-1 M4TiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zTVmlEPTB;MUOuN|Q2KM7:TR?= NWHrUFJHW0GQR1XS
IST-MES1 NELte5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF|Lk[3Nlkh|ryP NH25S2pUSU6JRWK=
CTB-1 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe0U5dKSzVyPUGzMlczQTRizszN NFfQdm9USU6JRWK=
HUTU-80 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjGcpNtUUN3ME2xN{44PTd|IN88US=> NF7GOo9USU6JRWK=
LAN-6 NYLFO3hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF2LkK0OVch|ryP M163fnNCVkeHUh?=
KP-N-YS NX7nUmxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nxOWlEPTB;MUSuNlg6PCEQvF2= M4PSfXNCVkeHUh?=
CCRF-CEM NYDyVYtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF2LkSxOlkh|ryP NGmzd41USU6JRWK=
NCI-H1770 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF2LkWzOlkh|ryP MmX3V2FPT0WU
MZ2-MEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF3LkKyOVEh|ryP NF65TnRUSU6JRWK=
COR-L88 M4WzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jlNmlEPTB;MU[uNFAyOiEQvF2= MlHiV2FPT0WU
LOXIMVI MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\VfGlKSzVyPUG2MlI2PiEQvF2= NV;4PHUzW0GQR1XS
KALS-1 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HsSGlEPTB;MU[uOVk{OSEQvF2= NGPuOFZUSU6JRWK=
D-283MED MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPpTWM2OD1zNj64OFg6KM7:TR?= MVvTRW5ITVJ?
NCI-H719 NGDSOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HhbGlEPTB;MU[uPVE3OSEQvF2= MYnTRW5ITVJ?
MLMA NFH5RYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L4SWlEPTB;MU[uPVkxPyEQvF2= MoLEV2FPT0WU
EVSA-T NIPlZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DxV2lEPTB;MUeuNFQ5PSEQvF2= M3ridXNCVkeHUh?=
SK-N-FI M2fmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHKfm5KSzVyPUG3MlY6OTNizszN M3jZU3NCVkeHUh?=
NTERA-S-cl-D1 M2XSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrVeWNKSzVyPUG3Mlg2PzJizszN M3\ZWXNCVkeHUh?=
NCI-H1882 NGfwWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7FfXBJUUN3ME2xO{46QDN2IN88US=> NWLhZpFoW0GQR1XS
A704 MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3tTWM2OD1zNz65PVA1KM7:TR?= NVLJcG9MW0GQR1XS
L-428 M4TaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET5fFFKSzVyPUG4MlAyPTFizszN MofrV2FPT0WU
HCC1187 NUn4WlVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP4e5JKSzVyPUG4MlAyQDdizszN NH;KW5RUSU6JRWK=
NCI-H1581 M37jdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;pZppxUUN3ME2xPE4xQDZ4IN88US=> NFHrVJBUSU6JRWK=
BB65-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nmTWlEPTB;MUiuOFE3OiEQvF2= NFHxSlRUSU6JRWK=
EM-2 NVq4UnM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TXTGlEPTB;MUiuOVY4OiEQvF2= M2XURXNCVkeHUh?=
Raji M{PLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULBWJFIUUN3ME2xPU46PTZ3IN88US=> MnLDV2FPT0WU
TE-1 NUX5[GdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJyLkSxNFQh|ryP NXK1Wpg4W0GQR1XS
SW962 NGq5bJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrJTWM2OD1{MD60Nlk{KM7:TR?= NGLsfpRUSU6JRWK=
MHH-NB-11 M1\oPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;1TWM2OD1{MD61OVIyKM7:TR?= NYrQUXQ1W0GQR1XS
no-10 M1XyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi0TWM2OD1{MT6wNlY1KM7:TR?= MUXTRW5ITVJ?
GDM-1 M2SyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7Qfnd7UUN3ME2yNU46PDF2IN88US=> MYLTRW5ITVJ?
KMS-12-PE MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPifXd1UUN3ME2yNk4zPzRizszN Mln1V2FPT0WU
NCI-H510A M1nHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJ2LkGyO|gh|ryP M1nhT3NCVkeHUh?=
ES5 M1mxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rx[2lEPTB;MkSuO|M1QSEQvF2= NHGxeoxUSU6JRWK=
JiyoyeP-2003 M3:xVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rvcGlEPTB;Mk[uNlc1OiEQvF2= NGH4c2tUSU6JRWK=
NMC-G1 M2\MRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH2PIdKSzVyPUK3MlE5OjJizszN NFnEdWRUSU6JRWK=
NCI-H446 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ5LkS5OFYh|ryP M3jCPXNCVkeHUh?=
NB7 NInBO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;OTWM2OD1{Nz65NlI6KM7:TR?= NGPsSmpUSU6JRWK=
A388 M{jYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom5TWM2OD1{OD6wNFc1KM7:TR?= NYH5SplKW0GQR1XS
JVM-2 NUHkXGV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECyRYpKSzVyPUK4MlI5QThizszN MXXTRW5ITVJ?
HT-144 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS1cohKSzVyPUK4MlY6KM7:TR?= NEGwSYtUSU6JRWK=
NCI-H747 M3rvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TDdmlEPTB;MkiuPVE6PSEQvF2= MoDZV2FPT0WU
NCI-H1650 NYrXflB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X6U2lEPTB;MkmuNFE4PiEQvF2= NVTCTZJwW0GQR1XS
EB-3 NUm5[2czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\yZnFKSzVyPUK5MlU{ODlizszN MUPTRW5ITVJ?
KLE MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XuTWlEPTB;MkmuOlE6KM7:TR?= MmHDV2FPT0WU
TK10 NFjufWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr4[2ZKSzVyPUOwMlEzPiEQvF2= MVvTRW5ITVJ?
COLO-668 M2rwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnWTWM2OD1|MD63PVIh|ryP NXTrVXFjW0GQR1XS
NCI-H23 M13qUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHlTFRsUUN3ME2zNU4yODZ|IN88US=> MnXzV2FPT0WU
GOTO Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzsSJJKSzVyPUOxMlYxQDVizszN NF7KTXVUSU6JRWK=
MSTO-211H M1nnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13BSmlEPTB;M{GuPFY4QCEQvF2= Mn;6V2FPT0WU
LB831-BLC NXq2SWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPjVIJTUUN3ME2zNk4{QDR|IN88US=> NIfEdZlUSU6JRWK=
SCH NHu2R4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW3[mNKSzVyPUOyMlg1QDVizszN MUTTRW5ITVJ?
EHEB MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfXR29jUUN3ME2zOE4yOTl|IN88US=> MYDTRW5ITVJ?
U-266 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCwXFdDUUN3ME2zOE4zPzhzIN88US=> NWe4NIN7W0GQR1XS
EW-11 NUfTPG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH1d5FJUUN3ME2zOE41PzJ3IN88US=> M3zpdXNCVkeHUh?=
TE-9 NIXMeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL5[YZKSzVyPUO3MlA1ODFizszN MVnTRW5ITVJ?
ES3 NY\5dJZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTN5LkWwNFQh|ryP NWfnc|ZuW0GQR1XS
NCI-H2141 M1TlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN6LkC4OFMh|ryP MYLTRW5ITVJ?
MPP-89 NHP4WYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvGPXBKSzVyPUSyMlA2QDZizszN MnXFV2FPT0WU
SK-MEL-2 NEj4fVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXmbJVGUUN3ME20Nk43PDB3IN88US=> MWLTRW5ITVJ?
LC-1F M33Mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDm[W9IUUN3ME20N{4{Pjh{IN88US=> M4jJNHNCVkeHUh?=
NH-12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13mcGlEPTB;NEOuPVM2QSEQvF2= MYnTRW5ITVJ?
RKO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPtO4JKSzVyPUS0MlEzPTJizszN MnywV2FPT0WU
KM-H2 NIK0eGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzSRY1KSzVyPUS0Mlk2PzdizszN MoLNV2FPT0WU
SK-UT-1 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTR7Lki4NlUh|ryP NFTxfYtUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03463460 Suspended Thymic Carcinoma Dwight Owen|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center June 19 2018 Phase 2
NCT03463460 Suspended Thymic Carcinoma Dwight Owen|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center June 19 2018 Phase 2
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma National Cancer Institute (NCI)|Canadian Cancer Trials Group April 5 2016 Phase 2
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma National Cancer Institute (NCI)|Canadian Cancer Trials Group April 5 2016 Phase 2
NCT02779283 Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) January 13 2016 Phase 1
NCT02779283 Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) January 13 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products4

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID